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Background: In addition to possessing intracellular vesicles, eukaryotic cells also produce extracellular microvesicles,
ranging from 50 to 1000 nm in diameter that are released or shed into the microenvironment under physiological
and pathological conditions. These membranous extracellular organelles include both exosomes (originating from
internal vesicles of endosomes) and ectosomes (originating from direct budding/shedding of plasma membranes).
Extracellular microvesicles contain cell-specific collections of proteins, glycoproteins, lipids, nucleic acids and other
molecules. These vesicles play important roles in intercellular communication by acting as carrier for essential
cell-specific information to target cells. Endothelial cells in the brain form the blood–brain barrier, a specialized
interface between the blood and the brain that tightly controls traffic of nutrients and macromolecules between
two compartments and interacts closely with other cells forming the neurovascular unit. Therefore, brain
endothelial cell extracellular microvesicles could potentially play important roles in ‘externalizing’ brain-specific
biomarkers into the blood stream during pathological conditions, in transcytosis of blood-borne molecules into the
brain, and in cell-cell communication within the neurovascular unit.
Methods: To study cell-specific molecular make-up and functions of brain endothelial cell exosomes, methods for
isolation of extracellular microvesicles using mass spectrometry-compatible protocols and the characterization of
their signature profiles using mass spectrometry -based proteomics were developed.
Results: A total of 1179 proteins were identified in the isolated extracellular microvesicles from brain endothelial
cells. The microvesicles were validated by identification of almost 60 known markers, including Alix, TSG101 and the
tetraspanin proteins CD81 and CD9. The surface proteins on isolated microvesicles could potentially interact with
both primary astrocytes and cortical neurons, as cell-cell communication vesicles. Finally, brain endothelial cell
extracellular microvesicles were shown to contain several receptors previously shown to carry macromolecules
across the blood brain barrier, including transferrin receptor, insulin receptor, LRPs, LDL and TMEM30A.
Conclusions: The methods described here permit identification of the molecular signatures for brain endothelial
cell-specific extracellular microvesicles under various biological conditions. In addition to being a potential source of
useful biomarkers, these vesicles contain potentially novel receptors known for delivering molecules across the
blood–brain barrier.
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Brain endothelial cells (BEC) lining the brain capillaries
are sealed by tight junctions and exhibit a specialized mo-
lecular and functional phenotype referred to as the blood–
brain barrier (BBB). The BBB functions as a physical and
enzymatic barrier and employs polarized transport sys-
tems to control the exchange of nutrients and macromole-
cules between the blood and the brain [1]. BECs are
tightly integrated with other neighbouring cells, pericytes
and astrocytes; astrocytes also communicate with neurons
acting as a liaison for endothelial–neuronal coupling (the
neurovascular unit; NVU). The luminal, blood-facing sur-
face of BEC is endowed by a thick and dynamic glycocalyx
involved in sensing the microenvironment and interac-
tions with blood-borne cells. With the surface area of
~20 m2 in the human brain, BECs are a potential source
of diagnostic/prognostic blood-accessible biomarkers
characteristic of brain pathologies.
Whereas the BBB is a hindrance for delivery of thera-
peutics, especially macromolecules, to brain targets, spe-
cific BEC receptors that undergo receptor-mediated
transcytosis (RMT) have recently been exploited for the
development of ‘Trojan horses’ – molecular ligands to
these receptors that can ‘piggy-back’ therapeutics across
the BBB. The current spectrum of known BBB receptors
that undergo RMT is limited, and only a few, including
the transferrin receptor (TFRC) [2,3], insulin receptor
(INSR) [4,5] and low density lipoprotein receptor-related
protein 1 (LRP1) [6,7] have been used for brain delivery of
macromolecules with varying success [7,8]. Mechanisms
for the RMT process remain poorly understood; despite
the surge in literature on intracellular sorting processes
leading to receptor endocytosis and recycling, the nature
of ‘transcytosing vesicles’ of the BBB remains obscure.
Most eukaryotic cells secrete a mixed population
of extracellular microvesicles (EMVs). The EMVs are
released either through exocytosis of multivesicular bod-
ies (MVBs) forming 50-100 nm-diameter exosomes
or through shedding of plasma membranes forming
100-1000 nm-diameter shedding vesicles or ectosomes
[9-11]. EMVs have been isolated using differential centri-
fugation methods [12,13] from cultured supernatants
and body fluids including cerebrospinal fluid . EMVs ori-
ginating from different cells and tissues have been ana-
lysed using electron microscopy and various molecular
methods, including proteomics [14], and the results of
these analyses have been compiled as the database of
proteins, miRNAs and lipids known as ExoCarta [15].
EMVs are released by various CNS cells [16-18] and
endothelial cells [19], including fetal brain endothelium
undergoing angiogenic sprouting [20].
EMVs contain RNA and proteins that are specific to
the original cell type. For example, tumor-derived exo-
somes usually contain tumor –specific antigens as wellas certain immunosuppressive proteins such as FasL,
TRAIL, or TGF-β [9,21]. This cell-derived specificity
and accessibility from body fluids [13] has made EMVs
an attractive source of biomarkers for transcriptomic
and proteomic studies. BBB-specific EMVs that are shed
or secreted into the blood could be a source of biomarkers
specific for CNS disorders.
Various studies have now demonstrated that EMVs are
a general vehicle for cell-cell communication [10,11].
EMVs carry cell-specific protein and RNA cargo and
horizontally transfer these molecules into the target cell,
resulting in a rapid change in transcriptome and prote-
ome of the target cell. A similar function of BBB-derived
EMVs in the cross-talk among cells of the NVU could
be envisaged, in view of recently-described role of EMVs as
communication vehicles among the various parenchymal
cells of the CNS [16,22,23].
We propose that EMVs derived from BECs have the po-
tential to be (i) a source of BEC/CNS specific biomarkers;
(ii) communication vesicles within neurovascular unit, and
(iii) ‘transcytosing vesicles’ containing specific RMT recep-
tors. These hypothesized functional roles for BEC EMVs
are illustrated in Figure 1. This study provides initial sup-
porting evidence for these proposed roles through analyses
of molecular signatures of BEC EMVs using sensitive mass
spectrometry (MS)-based proteomics protocols.
Methods
HBEC cultures
The immortalized human brain microvascular endothelial
cells, HCMEC/D3 [24], were used in this study and are re-
ferred to as HBEC throughout the manuscript. HCMEC/
D3 cell line was obtained from Dr. Pierre Olivier Couraud
(Cochin Institute, Université Paris DescartesINSERM.
The cells were grown in a humidified atmosphere of
5% CO2/95% O2 at 37°C in EBM-2 basal medium
(Lonza, Walkersville, MD, USA), supplemented with one
quarter of a SingleQuot kit (Lonza) and 2% fetal bovine
serum in flasks coated with 100 μg/ml rat tail collagen
type I (BD Canada, Mississauga, ON,Canada), diluted in
20 mM acetic acid. Cells from passages 30 to 34 were
used. EMV production was done in serum-free conditions
since serum has endogenous EMVs and serum molecules
can non-specifically bind to HBEC-EMVs. To prepare for
EMV isolation, cells were grown until confluence, washed
at least three times with a buffered-saline solution and
then incubated in serum-free medium for at least 1 d to
obtain a sufficient amount of EMVs. While this protocol
was optimized for HBEC, any mammalian cell type can be
used as a starting sample for EMV isolation.
Isolation of EMVs from HBEC
EMV isolation method was adapted from [13]. Typically

































Figure 1 Proposed functions of extracellular microvesicles
(EMVs) at the blood–brain barrier. EMVs ‘shed’ from the luminal
membranes of BEC into the circulation contain unique molecules
(as indicated by star) that potentially can be used as CNS-specific
markers. Ligand binding to receptor-mediated transcytosis (RMT)
receptor on the luminal surface leads to receptor-mediated
endocytosis. The ligand/receptor complex is then sorted through
the endocytic pathway into multivesicular bodies (MVBs) and is
externalized on the abluminal side in abluminal EMVs. The EMVs can
communicate with cells in the brain, including neurons and
astrocytes through protein-protein surface interactions followed by
transfer of RNA/protein molecules. A similar process may occur in
the opposite direction, resulting in RMT receptor recycling, or
‘transfer’ of parenchymal exosomes into the systemic circulation.
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for 10 min at 4°C to remove any intact cells, followed by
a 2,000 ×g spin for 20 min at 4°C to remove dead cells
and finally a 10,000 ×g spin for 30 min at 4°C to remove
cell debris. The media was then transferred toultracentrifuge tubes and centrifuged at 100,000 ×g for
at least 60 min at 4°C in Optima TLX ultracentrifuge
with 60 Ti rotor (Beckman Coulter, Mississauga,
Canada). The supernatant containing EMV-free media
was removed and the pellets containing EMVs plus pro-
teins from media were resuspended in PBS. The suspen-
sion was centrifuged at 100,000 ×g for at least 60 min at
4°C to collect final EMV pellets. Typically this method
provided enough exosomes to be analyzed at least seven
times by gel-free nanoLC-MS/MS methods (FASP, DR)
or 1-3 times by gel-based methods (SDS-PAGE, Gel-LC-
MS/MS or Western blotting).
Proteomics methods
Three methods were used and compared for isolating pro-
teins from EMVs: (i) detergent removal (DR), (ii) filtered-
aided sample preparation (FASP) [25] and (iii) 1D-SDS-
PAGE (gel-LC). For the DR and gel-LC methods, EMVs
were dissolved in 50 mM Tris–HCl (pH 8.5), 0.2% SDS by
boiling for 10 min. The samples were reduced (4 mM
DTT for 10 min at 95°C) and alkylated (10 mM iodoaceta-
mide, 30 min at room temperature in dark) and divided
for DR and gel-LC analysis. For DR, SDS was removed
using detergent removal spin columns (Pierce, Rockford,
IL, USA) by washing against 50 mM Tris–HCl (pH 8.5)
and the samples were digested overnight using trypsin
(Promega, Madison, WI, USA) at 37°C for nanoLC-MS/
MS analysis. For gel-LC, samples were separated on one-
dimensional SDS-PAGE and stained with Coomassie blue
to identify the proteins. The entire lane was cut into
ten sequential bands. Each band was de-stained and
was in-gel digested using trypsin at 37°C for nanoLC-MS/
MS analysis.
For FASP method, EMVs were reduced in 3.5% SDS,
100 mM Tris–HCl, 100 mM DTT by boiling for 10 min.
A 6.6-volume of urea solution (8 M urea, 100 mM Tris–
HCl, pH 8.5) was added to the sample and they were
transferred to pre-wetted Amicon-30 spin columns
(Millipore, Billerica, MA, USA) and spun as per manu-
facturer’s instructions. The proteins were washed three
times with the urea solution, alkylated (10 mM iodoace-
tamide, 30-60 min at room temperature in dark), and
then washed four times with the urea solution and four
times with 50 mM ammonium bicarbonate. The samples
were digested using trypsin at 37°C and the peptides
were eluted for nanoLC-MS/MS analysis.
NanoLC-MS/MS and data analysis
The digested proteins were acidified with acetic acid (5%
final concentration) and analyzed on a reversed-phase
nanoAcquity UPLC (Waters, Milford, MA, USA) coupled
to LTQ Orbitrap ETD mass spectrometer (ThermoFisher,
Waltham, MA, USA). The analysis involved injection and
loading of the desired aliquot of the sample onto a
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(ThermoFisher) followed by eluting onto a 100 μm I.D. ×
10 cm 1.7 μm BEH130C18 nanoLC column (Waters)
using a gradient from 0% - 20%% acetonitrile (in 0.1% for-
mic) in 1 min, 20% - 46% in 60 min, and 46% - 95% in
1 min at a flow rate of 400 nL/min. The eluting peptides
were ionized into the mass spectrometer by electrospray
ionization (ESI) for MS/MS using collision-induced dis-
sociation (CID) for fragmentation of the peptide ions.
Data was acquired on ions with mass/charge (m/z) values
between 400 and 2,000 with 1.0 s scan duration and 0.1 s
interscan interval. All MS/MS spectra were obtained on 2+,
3+, and 4+ ions. The raw data was converted to mzXML
format and peak lists were submitted to a probability-based
search engine, Mascot version 2.2.0 (Matrix Science Ltd.,
London, UK) [26]. The initial database utilized was a com-
posite of forward and reverse Uniprot-Swiss-Prot Homo
sapiens protein database (July 2012). Unmatched peptides
were subsequently searched against the entire Uniprot-
Swiss-Prot database (July 2012). Searches were performed
with a specified trypsin enzymatic cleavage with one pos-
sible missed cleavage. False-positive rate (FPR) in Mascot
searching was calculated as follows:
FPR ¼ 2Nrevð Þ= Nrev þNfwdð Þ;
where Nrev is the number of peptides identified (after filter-
ing) from the reverse-database, and Nfwd is the number of
peptides identified (after filtering) from the forward data-
base. To maximize the number of peptides and keep the
FPR <0.5%, ion scores >40, parent ion tolerance of < 0.1 Da,
a fragment ion tolerance of < 0.2 Da, and minimal number
of missed cleavages were chosen (≤1). As an independent
statistical measure of peptide identification, Peptide Prophet
probabilities were also measured. All identified peptides
had p ≥ 0.90. To measure the MS signal, intensities of all
the ions in the MS run were extracted from the mzXML
files using MatchRx software as described previously [27].
MS signal from a group of proteins was obtained by sum-
ming intensities of ions (peptides) associated with these
proteins. Total MS signal was calculated by summing inten-
sities of all the ions in the MS run.
Detection of FC5 in EMVs using western blotting analysis
or LC-MRM
For Western blotting, EMV proteins were extracted by
boiling 5-10 min in Laemmli buffer (BioRad, Hercules,
CA, USA) containing fresh 5%% beta-mercaptoethanol
(Sigma-Aldrich, St. Louis, MO, USA). Protein extracts
were resolved on a 12% discontinuous SDS-PAGE and ei-
ther silver stained or electrophoretically transferred onto
nitrocellulose membranes (Millipore, Nepean, Canada).
Membranes were blocked in 5% non-fat dry milk powder
in TBST buffer (10 mM Tris, pH 7.4, 150 mM NaCl,0.02% Tween-20) for 2 h. Anti-VHH rabbit polyclonal
antibody (Biogen Idec, Cambridge MA, USA) was diluted
at 1:1000 in 2.5% milk in TBST and incubated with the
membranes for 18 h at 4°C. Membranes were washed 4
times in TBST and then incubated for 1 h with goat anti-
rabbit-HRP (Sigma-Aldrich), diluted 1:8000 in TBST.
Membranes were washed 4 times with TBST and then
developed by ECL Plus Chemiluminescent Substrate
(GE Healthcare).
For LC-MRM based detection of FC5, a sensitive and
specific method recently described for detection of VHHs
in body fluids was utilized [28]. Briefly, the FASP-extracted
EMVs described above were reanalyzed using the LTQ
OrbitrapW in SRM mode and monitor FC5-specific signa-
tures. This involved selecting the precursor m/z of 844.92
for FC5-specific peptide ITWGGDNTFYSNSVK and
monitoring signature fragment ions 534.48, 729.47, 737.89,
1288.44. For quantification analysis, raw files generated by
LTQ were converted to mzXML format and intensities
were extracted using an in-house software Q-MRM, a
modified version of MatchRx software [27].
Results
Proteomics of HBEC-EMVs
EMVs were isolated from HBEC using the method
shown schematically in Figure 2A; the protocol included
extensive washing to minimize cell debris, artifacts and
contaminating proteins. Three proteomics methods were
then used for the molecular analysis of the isolated
EMVs. These included gel-LC (1D-SDS-PAGE-LC-MS/
MS) and gel-free methods, FASP and DR.
Figure 2B shows the number and overlap of proteins
identified by each of these methods; 133 proteins were
common amongst all three methods. The gel-free meth-
ods identified more proteins than the gel-LC and the
overlap between the gel-free methods was also the high-
est (286 proteins); the FASP method identified the high-
est number of proteins. Since many proteins were still
specific to gel-LC and DR methods, the gel-free and gel-
based methods were considered complementary. In all, a
total of 1179 proteins were identified in the EMVs of the
immortalized HBEC using proteomics.
Are HBEC-EMVs proteins identified by proteomics
intact proteins?
Since EMVs (especially exosomes) are known to originate
from the cellular endocytic pathway that could include
lysosomes and their digestive enzymes, there was a possi-
bility that the EMVs may contain a large number of
degraded proteins. To assess whether proteins identified
from HBEC-EMVs by above methods are intact proteins,
we examined if they separated on 1D-SDS-PAGE accord-
ing to their expected molecular weight (MW). After separ-














300 g to remove cells
2,000 g to remove dead cells
10,000 g to remove cell debris
100,000 g to pellet EMVs plus contaminants
Wash away contaminants
100,000 g to collect EMVs
Proteomics method (FASP, gel-LC, DR)
NanoLC-MS/MS analysis
A) B)
Figure 2 Proteomics of human brain endothelial cell extracellular microvesicles (HBEC-EMVs). (A) Workflow of the EMV isolation from
HBEC media. (B) Venn diagram showing the overlap among the identified proteins by 3 proteomics methods used for analysis of EMVs. FASP:
filtered-aided sample preparation, gel-LC: gel electrophoresis followed by nanoLC-MS/MS, DR: detergent removal. See Methods for more details.
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lowed by nanoLC-MS/MS analysis to identify proteins in
each gel band (Figure 3A). For comparison, HBEC-whole-
cell extracts (WCEs) were also similarly analyzed by gel-
LC. Shown in Figure 3 are the total number of proteins
identified by gel-LC (Figure 3B) and the average expected
(theoretical) MWs of the proteins in each gel band
(Figure 3C) in HBEC-EMVs and HBEC-WCEs. Also
shown are the observed MWs of the proteins (Figure 3C,
dotted lines), as estimated from the MW markers
(Figure 3A). The results show that the majority of proteins
ran at or above their expected MW suggesting that they
are not degraded or truncated. Only about 20% of the MS
signal in HBEC-EMVs (Figure 3D) originated from
degraded proteins. These results were closely comparable
to gel-LC of WCEs (Figure 3C), which show about 24% of
the MS signal (Figure 3D) from degraded proteins.
The proteins identified in the top two bands of gel-LC
of HBEC-EMVs were found to run at significantly higher
MW than expected and, for some, higher than their
observed MW in WCEs. Most of these proteins are
known glycoproteins (including adhesion molecules and
other membrane proteins). This observation suggests that
the proteins in bands 1 and 2 of HBEC-EMVs are poten-
tially glycosylated, a post-translational modification that
can stabilize proteins from degradation, especially against
digestive enzymes in the lysosomes.
EMV-specific and HBEC-EMV-specific markers
More than 60 known markers of EMVs have been previ-
ously described [14]. In addition, >2000 proteins associatedwith Homo sapiens have been identified in ExoCarta, a
large proteomics database of exosomes and EMVs in
various human cell types [15]. To demonstrate that the
HBEC-EMVs isolated by described methods are pure
and contain known EMV-specific markers, we com-
pared the 1179 identified HBEC-EMV proteins against
the 60 known EMV markers in the ExoCarta database.
As shown in Figure 4A, the majority of known exosome
markers (58 of 65, Table 1) and many other ExoCarta-
catalogued proteins were detectable in HBEC-EMVs.
Importantly, 524 proteins identified in HBEC-EMVs did
not overlap with proteins in ExoCarta, suggesting that
they may be HBEC-specific. These signatures consisted
of 35% cell-surface and 65% intracellular proteins and
were further classified using Gene Ontology and Pan-
ther classification system (Figure 4B).
We also examined the percentage of the MS signal
originating from the known exosome proteins identified
in HBEC-EMVs (Table 1). As shown in Figure 4C, >55%
of the MS intensities was attributable to known 60 EMV
markers and their families in HBEC-EMVs, a 3.3-fold
higher than the signal from same proteins in HBEC-
WCEs (p < 0.001, Mann Whitney U-test). Similarly,
about 80% of the signal in HBEC-EMVs originated from
ExoCarta-catalogued proteins, which was also signifi-
cantly higher than the signal in HBEC-WCEs (2.4-folds,
p < 0.01, Mann Whitney U-test). These results suggest
that HBEC-EMVs obtained by described methods are
highly enriched with known markers of exosomes, but
also harbour many protein signatures that are specific
to HBEC.



































































































Figure 3 Gel-LC MS/MS of HBEC-EMV proteins. (A) Coommassie blue-stained gel following SDS-PAGE analysis of EMVs from HBEC. Shown are
the molecular weight (MW) markers (left) and the position of ten bands that were cut out (right). (B) Total number of proteins identified in each
band from SDS-PAGE of EMVs (left) or whole-cell HBEC extract (right). (C) Average theoretical MW (± SD) of the proteins in each gel band. The
dotted lines represent the observed MW range of gel band, as determined by marker lane. If the theoretical MW is above the upper dotted line,
it is likely degraded/truncated, whereas if it is below the lower dotted line, it is potentially post-translationally modified. Note the log scale. (D)
Percentage of MS signal originating from degraded/truncated proteins in each gel band as described in panel C.
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Communication between cells, including horizontal trans-
fer of RNAs and proteins, is the main physiological role of
EMVs; the ‘generic’ map of surface molecules and intrave-
sicular content of EMVs (Figure 5A) uniquely reflects
their function in cell-cell communication.
To examine whether the identified proteins in HBEC-
EMVs have known roles associated with cell-cell commu-
nication, the 1179 identified proteins were categorized
based on their known functional and biological classes
using a combination of Gene Ontology database and Pan-
ther classification system. Most of the proteins could be
classified into 8 key categories as shown in Figure 5B.
These included key biological processes such as intracellu-
lar trafficking, signal transduction, cell adhesion, and cell
motility. In addition, they included functional classes
such as RNA/DNA-binding proteins, receptors, structuralproteins and enzymes. A number of these categories were
determined to be statistically over-represented when the
1179 proteins were compared to one-hundred random
lists of 1179 proteins sampled from Uniprot human data-
base. The classes overrepresented included membrane
traffic proteins (p < 0.001), RNA/DNA-binding proteins
(p < 0.001), cytoskeletal structural proteins (p < 0.001), and
enzymes (p < 0.01).
To assess whether BEC-EMVs are capable of interact-
ing with cells of the CNS, we analysed in silico whether
the surface molecules on HBEC-EMVs could form
protein-protein interactions with cell-surface molecules
on astrocytes and neurons using in situ cell-cell interac-
tomics approach, recently described by us for HBEC and
Th17 cells [29]. The data was obtained from (in house)
proteomics maps of primary human astrocytes (unpub-




























































Figure 4 EMV-specific and HBEC-EMV-specific markers (A) Venn diagram showing overlap among HBEC-EMVs, known 65 EMV markers
(dotted circle), and ExoCarta proteins. (B) Subclassification of the 524 HBEC-EMV-specific proteins (panel A). (C) Percentage of total MS signal
originating from proteins in common with known 65 EMV markers or ExoCarta in HBEC-EMVs and whole HBEC extracts. The ** corresponds to
p < 0.01 and *** corresponds to p < 0.001 for Mann Whitney U-test with n = 3.
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proteins of HBEC-EMVs could interact with 30 cell-
surface proteins of human astrocytes forming 58 theoret-
ical protein-protein interactions. Similarly, 35 HBEC-EMV
surface proteins could interact with 39 neuronal surface
proteins forming 87 theoretical protein-protein interac-
tions. While these identified interactions are hypothetical
and will require validation in co-culture assays, they indi-
cate that EMVs released from HBECs can potentially
interact as cell communication vesicles with both primary
astrocytes and cortical neurons.
Receptor-mediated transcytosis receptors in HBEC-EMVs
Several BBB-expressed receptors are known to undergo a
receptor-mediated transcytosis (RMT). To examine
whether these receptors could be found in HBEC-EMVs,
we first compared 1179 proteins identified in HBEC-
EMVs with proteins identified in plasma membranes and
endocytic membranes of HBEC. As shown in Figure 6A,about 50% of the HBEC-EMV proteins were common
with those identified in either endocytic- or plasma mem-
branes of HBEC. Endocytic pathway proteins were shown
to contribute to >30% of all proteins identified in HBEC-
EMVs. We next examined whether known RMT recep-
tors– especially those previously explored for therapeutic
drug delivery across the BBB – were also present in the
HBEC-EMVs. As shown in Table 2, several known recep-
tors for BBB ‘Trojan horses’ were found in HBEC-EMVs,
including TMEM30A, a putative antigen for the single-
domain antibody, FC5, shown to transmigrate the BBB
in vitro and in vivo [31-33](manuscript submitted). To
confirm that FC5 could be ‘shuttled’ by HBEC-EMVs, the
RMT was initiated by the addition of FC5 to HBEC, and
EMVs collected from these cells were analysed by proteo-
mics and Western blotting. FC5 was clearly detectable in
the EMVs by Western blotting using polyclonal anti-VHH
antibody (Figure 6B). The presence of FC5-specific signal
in BEC EMVs was additionally confirmed and quantified
Table 1 Proteins identified in HBEC-EMVs by proteomics
















Myosin, heavy MYH 5
Myosin, light MYL 3
Radixin RDX 1
Tublins TUB 13
(4) Heat shock proteins and chaperones
Heat shock cognate 71 kDa protein HSPA8 1
T-complex protein 1 CCT 8
(5) Metabolic enzymes
Aldolase A ALDOA 1




Phosphoglycerate kinase 1 PGK1 1
Phosphoglycerate mutase 1 PGAM1 1
Pyruvate kinase isozymes M1/M2 PKM2 1
(6) Multi vesicular body (MVB) biogenesis
Alix PDCD6IP 1
ESCRT I complex
Tumor susceptibility gene 101 protein TSG101 1











Vacuolar-sorting protein SNF8 SNF8 1
ESCRT III complex
Charged MVB proteins CHMP 2
(7) Signaling proteins
14-3-3 Proteins YWHA 6
GTPase HRas HRAS 1




Table 1 Proteins identified in HBEC-EMVs by proteomics
that were in common with known markers of exosomes*
(Continued)
Ras-related protein Rap-1b RAP1B 1
Ras-related protein R-Ras2 RRAS2 1
Ras GTPase-activating-like protein IQGAP1 1
Syntenin-1 SDCBP 1
Transforming protein RhoA RHOA 1
Guanine nucleotide-binding protein
(G proteins)
-G(I)/G(S)/G(T) subunit beta GNB 4
Protein category and description
Gene symbol
-G(I)/G(S)/G(O) subunit gamma GNG 1
-G(S) subunit alpha GNAS 1
-subunit alpha GNA 4
-G(I), alpha GNAI 1
(8) Tetraspanins
CD9 antigen CD9 1
CD63 antigen CD63 1
CD81 antigen CD81 1
CD82 antigen CD82 1
(9) Transcription and protein synthesis
Histones HIST 14
Ribosomal proteins RPS 34
Ubiquitin RPS27A 1
Elongation factor 1-a 1 EEF1A1 1
(10) Trafficking and membrane fusion
Annexins ANXA 1
ADP-ribosylation factor ARF 3
AP-2 complex subunit α-1 AP2A1 1
AP-2 complex subunit β-1 AP2B1 1
Clathrin heavy chain 1 CLTC 1
Rab GDP dissociation inhibitor b GDI2 1
Ras-related protein Rab RAB 9
Synaptosomal-associated protein 23 SNAP23 1
* The known markers of exosomes were obtained from Simpson et al [14]. For
many proteins, more than one family member was detected.
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[28]. The presence of known RMT receptors and co-
localization of FC5 with its putative RMT receptor,
TMEM30A, in HBEC-EMVs suggest that these vesicles
might be implicated in RMT process across the BBB.
Discussion
This manuscript details methods for isolation as well as sen-
sitive MS-based protocols for molecular analyses of EMVs
from HBEC. Using these methods, 1179 unique proteins
were identified in HBEC-EMVs. These methods, in combi-
nation with bioinformatics tools, were used to demonstrate
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Figure 5 Subclassification of surface and intravesicular molecules in EMVs. (A) A ‘generic’ molecular map of EMVs. (B) Protein classification
of HBEC-EMVs using Gene Ontology and Panther.
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teins, (ii) contain a majority of known exosome-specific pro-
teins, as well as unique ‘signature’ proteins, (iii) contain
proteins implicated in receptor-mediated transcytosis across
the BBB.
Are EMVs artifacts?
EMVs were originally believed to be cellular artifacts and
thought of as mechanisms through which cells discard
inert debris [10,30]. Many reports have since shown that
EMVs are real, released cellular sub-compartments
that consist of subsets of few protein families.
The BEC EMVs isolated by the described differential
centrifugation method have not been morphologically
characterized and may include both small (100 nm) and
larger (up to 1000 nm) EMVs. Proteomic analyses of these
EMVs reported in this study confirmed that HBEC-EMVs
contain specific sub-sets of intact proteins, originating
from the plasma membrane, endocytic pathway(s) and the
cytosol. A subgroup of higher molecular weight proteins
represented in EMVs appear to be post-translationally
modified, compared to same proteins in whole-cell
extracts, suggesting that they may originate from compart-
ments characterized by high glycosylation, such as BEC
luminal membranes or endocytic vesicles(s).
Specificity of HBEC-EMVs
The diagnostic potential of EMVs has been aggressively
investigated [12,13], since they contain tissue and
disease-specific biomarker signatures [9,21]. The tissue-
specificity of EMVs is determined by specific RNA
sequences and specific cell-surface molecules. The BBB-
specific EMVs in body fluids could contain biomarkersuseful for diagnosis or monitoring of brain diseases,
since they could be ‘shed’ into the circulation from lu-
minal membranes of BEC and potentially shuttled across
the BBB from the abluminal side. We have found that
about 20% of the HBEC-EMVs MS signal originated
from proteins that were absent in exosomes from other
cell types, suggesting that these proteins are potentially
unique to HBEC-EMVs. Some of these included cell-
surface proteins, including adhesion molecules and other
cell-cell interacting molecules (Figure 4B).
The molecular signatures of EMVs can change under
different biological conditions (in vitro insults or dis-
eases state) [9,21]. For example, we have observed that
HBEC-EMVs molecular profile changed significantly in
response to inflammatory insults (unpublished data).
Therefore, monitoring HBEC-EMV-specific and disease-
modified RNAs, proteins, glycoproteins and glycans in
blood-derived EMVs by targeted ‘omics’ has potential
diagnostic significance for CNS disorders. However, the
utility of BBB EMVs as a source of disease-specific bio-
markers remains to be validated in further in vitro and
in vivo studies.
HBEC-EMVs as a vehicle for cell-cell communications
in CNS
The cell-cell communication mediated by EMVs occurs
predominantly by two processes: surface contact of vesi-
cles with cells triggering donor cell signaling pathways,
and/or delivery of vesicle content into the recipient cell
(endogenous transduction). Consistent with these roles in
cell-cell communication, the surface of EMVs is typically
enriched in cell-targeting/adhesion molecules (e.g., tetra-













































Figure 6 HBEC-EMV origin and receptor-mediated transcytosis
(RMT) receptors. (A) Number of proteins in HBEC-EMVs that are in
common with HBEC endocytic proteins and/or HBEC plasma
membrane proteins. Most of the RMT receptors shown in Table 2
were in common with plasma + endocytic membranes. (B)
Detection of FC5 in HBEC-EMVs from either control cells or cells
treated with 5 μg/mL of FC5 for 24 h in serum-free conditions using
Western blot analysis with polyclonal anti-VHH antibody (obtained
from Biogen Idec, Cambridge, MA, USA). Equal volume amounts
were loaded and the blot is a representative blot of n > 3. (C) Levels
of FC5-specific peptide detected by MRM as described in Methods.
The levels are relative to median “untreated” values. *** represents
p < 0.001 for Mann–Whitney U-test with n = 3.
Table 2 Known BBB RMT receptors identified in HBEC-EMVs
Receptor B
Transferrin Receptor (TFRC) O
Insulin Receptor (INSR) 8
Low-Density Lipoprotein Receptor (LDLR) C
LDLR-related proteins (LRP1, LRP1B, LRP2) P
Cell cycle control protein 50A (TMEM30A/CDC50A) F
Fc-Binding Proteins (e.g., FcγBP) F
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molecules (e.g., MHC class I and class II), and membrane
cytokines, whereas their luminal content mainly consists
of functionally-active RNAs (e.g., mRNA, microRNA, viral
RNA), RNA-binding proteins, ribosomes, functionally-
active proteins including enzymes (e.g., metalloproteases,
metabolic enzymes) and cytokines (Figure 5A). HBEC-
EMVs molecular make-up is consistent with this ‘generic’
exosome composition.
Given tight anatomical and functional integration of the
cellular elements of the neurovascular unit, including
BEC, pericytes, astrocytes and neurons, we surmise that
BEC exosomes could play similar roles in transducing in-
formation among the cells in the neurovascular unit. The
emerging role of neuronal exosomes in neuronal-glial
communication and inter-cellular transfer of signaling
miRNAs contributing to neuronal development and dis-
ease mechanisms has recently been reviewed [22]. The in
silico interactomics analyses confirmed that, based on mo-
lecular profile of HBEC-EMVs, they could engage in nu-
merous cell-surface interactions with both astrocytes and
neurons. Similar EMV-mediated communication could
occur among BEC and peripheral inflammatory cells
during processes of immune surveillance, rolling, adhesion
and transmigration.
Are HBEC-EMVs BBB ‘transcytosing’ vesicles?
The first discovery of exosomes, almost three decades
ago, involved detection of anti-TFRC antibody by elec-
tron microscopy in reticulocytes (summarized by Thery
et al [34]) in the following order: (i) on the surface of
the cells and clathrin-coated pits, (ii) inside early endo-
somes, (iii) on the surface of internal vesicles of multive-
sicular endosomes, and finally (iv) on the released
exosomes after fusion of the multivesicular endosomes
with the plasma membrane. The RMT pathway and exo-
some formation have notable similarities. The HBEC-
EMVs contained several receptors previously shown to
carry macromolecules across the BBB via RMT, includ-
ing TFRC, LRPs, LDLR, INSR and TMEM30A (Table 2).
A hypothetical pathway by which these receptors and
their ligands are ‘sorted’ into HBEC exosomes during
luminal-abluminal RMT process is shown in Figure 1. A




97 proteins and Angiopep peptides [6,39]
C5 sdAb [31-33]
c-containing antibodies
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http://www.fluidsbarrierscns.com/content/10/1/4direction, resulting in RMT receptor recycling, or ‘trans-
fer’ of parenchymal exosomes into the circulation. The
presence of known BBB RMT receptors in HBEC-EMVs
might suggest that, among 524 ‘unique’ proteins identi-
fied in HBEC-EMVs, there may be additional novel and
more specific RMT receptors exploitable for delivery of
macromolecules across the BBB.
Interestingly, after the addition of RMT-triggering
antibody FC5, we observed both a 4-fold increased
amount of EMVs being produced by HBEC (based on
total LC-MS signal; not shown) and presence of FC5
in these EMVs. This suggests that, under specific con-
ditions, brain endothelial cells could regulate the
amount of EMVs produced and ‘shed’ into abluminal
or circulatory space.
EMVs as BBB drug-delivery vehicles
The possibility of using exosomes as drug-delivery vehi-
cles, in particular for gene therapy with siRNAs, has
gained significant attention in recent literature. In the
study by Alvarez-Erviti et al [35], autologous exosomes
derived from dendritic cells engineered to express exoso-
mal membrane protein Lamp2b fused to the neuron-
specific RVG peptide, were loaded with exogenous
siRNA and shown to transduce brain parenchymal cells
knocking-down the therapeutic target, BACE1, after sys-
temic injection. Exosomes were also attempted as intra-
nasal delivery vehicle for anti-inflammatory drugs [36].
The advantage of self-derived exosomes over other lipid-
based nanocarriers is that they are immunologically inert
and are thought to possess ‘intrisic ability’ to cross bio-
logical barriers. Although this assertion requires further
confirmation, the possibility remains that tissue-specificity
of delivery could be improved by using homologous tissue
exosomes. Therefore, HBEC-EMVs could potentially be
exploited as brain-selective nanocarriers for therapeutic
delivery across the BBB.
Conclusions
The first comprehensive evaluation and cataloguing of
proteins expressed in EMVs derived from brain endothe-
lial cells described in this manuscript, demonstrated that
these vesicles contain common proteins typical of exo-
somes from different tissues, as well as proteins that
may be specific to unique functions of brain endothelial
cells within the context of the neurovascular unit, in-
cluding the transport of solutes and biologics across the
blood–brain barrier.
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